Drug
Hydroxyethylstarch 130 0 4
Hydroxyethylstarch 130 0 4: highest development phase Post-Market, developed by Fresenius Kabi. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Fresenius Kabi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Hydroxyethylstarch 130/0.4 NCT00308100 | Post-Market | Intraoperative Complications |
Latest
No recent events.
Follow Hydroxyethylstarch 130 0 4 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.